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Abstract
Although much recent focus has been on the recognition of Ebola virus disease among travelers 
from West Africa, cases of Middle East respiratory syndrome coronavirus (MERS-CoV), 
including travel-associated cases, continue to be reported. US clinicians need to be familiar with 
recommendations regarding when to suspect MERS-CoV, how to make a diagnosis, and what 
infection control measures need to be instituted when a case is suspected. Infection control is 
especially critical, given that most cases have been healthcare-associated. Two cases of MERS-
CoV were identified in the United States in May 2014; because these cases were detected 
promptly and appropriate control measures were put in place quickly, no secondary cases 
occurred. This paper summarizes information that US clinicians need to know to prevent 
secondary cases of MERS-CoV from occurring in the United States.
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Although much recent focus has been appropriately placed on the recognition of Ebola virus 
disease in travelers returning from West Africa, the recent increase in cases of Middle East 
respiratory syndrome coronavirus (MERS-CoV) infection (including travel-associated cases) 
is also of concern [1, 2]. MERS-CoV is a novel virus first reported in Saudi Arabia in 2012. 
As of 25 February 2015, a total of 1026 laboratory-confirmed cases of MERS-CoV 
infection, including at least 376 deaths (36.7%), have been confirmed by the World Health 
Organization (WHO) (Figure 1) [2]. Between 1 August 2014 and 25 February 2015, there 
have been 172 cases (and 69 deaths) confirmed by WHO, with an additional 16 cases and 12 
deaths pending WHO confirmation. All cases reported thus far have had a direct or indirect 
link through travel or residence to 9 countries in or near the Arabian Peninsula (Saudi 
Arabia, United Arab Emirates, Qatar, Oman, Jordan, Kuwait, Iran, Lebanon, and Yemen); at 
least 19 countries (including the United States) have had travel-associated cases (Figure 1). 
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Most MERS-CoV patients have had fever, cough, and shortness of breath, often leading to 
severe respiratory complications (eg, pneumonia or acute respiratory distress syndrome) [3, 
4]; some cases with mild or no symptoms (often tested as part of a contact investigation) 
have also been reported [5, 6]. Other reported symptoms include chills/rigors, headache, 
cough, dyspnea, myalgia, sore throat, coryza, dizziness, nausea/vomiting, diarrhea, and 
abdominal pain. Laboratory findings seen in some patients include leukopenia, 
lymphopenia, thrombocytopenia, thrombocytosis, and elevated levels of lactate 
dehydrogenase, alanine aminotransferase, and aspartate aminotransferase [3, 4]. In some 
MERS-CoV patients, coinfection with other respiratory pathogens has been reported [7, 8]; 
thus, identification of an alternative respiratory diagnosis should not rule out the possibility 
of MERS-CoV. The median age of persons with laboratory-confirmed MERS-CoV infection 
is 50 years, approximately 63% have been males, and approximately 18% have been 
healthcare workers [2]. Early on in the outbreak, a predominance of male patients and those 
with comorbidities was noted, and most cases had severe illness. However, as additional data 
are collected, the full spectrum of illness is becoming more clear, with a decrease in the 
percentage of severe cases and increase in asymptomatic cases, as well as a decline in the 
male-to-female ratio, median age, and case-fatality rate [9].
MERS-CoV transmission is not fully understood; however, many cases have had exposure(s) 
to healthcare settings during the 14 days before symptom onset (the median incubation 
period is approximately 5 days, with a range of 2–14 days). Recent data highlight the likely 
role of camels as a source of human infection in some cases (eg, MERS-CoV has been found 
in camels in the region; MERS-CoV gene sequences in camels are similar to those in 
humans; camels have had antibodies to MERS-CoV or a MERS-CoV–like virus, suggesting 
previous MERS-CoV infection; and full gene sequencing has linked MERS-CoV identified 
in a camel to a patient who died of MERS-CoV) [10–15]. On 1 May and 11 May 2014, 2 
cases of MERS-CoV infection were identified in Indiana and Florida, respectively [16, 17]. 
Both US cases were healthcare workers in Saudi Arabia and presented to hospitals in the 
United States with mild to moderate, nonspecific findings, where they were identified as 
having MERS-CoV by astute clinicians sensitized to the need to identify and test returning 
travelers with respiratory illnesses. Both patients were appropriately isolated and no 
secondary cases were identified despite extensive follow-up. These cases emphasize the 
importance of US clinicians’ becoming familiar with the clinical and epidemiologic features 
and actions needed to detect and manage MERS-CoV patients. The number of MERS cases 
has continued to increase; therefore, the risk of exportation of cases to the United States 
mandates that clinicians need to continue to be vigilant.
The Centers for Disease Control and Prevention (CDC) recommends evaluation for MERS-
CoV infection for the following patients [18]:
1. Patients with fever and clinical or radiographic evidence of pneumonia or acute 
respiratory distress syndrome and either a history of travel from countries in or 
near the Arabian Peninsula (Bahrain; Iraq; Iran; Israel, the West Bank, and Gaza; 
Jordan; Kuwait; Lebanon; Oman; Qatar; Saudi Arabia; Syria; the United Arab 
Emirates; and Yemen) within 14 days before symptom onset, or close contact 
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with a symptomatic traveler who developed fever and acute respiratory illness 
within 14 days after traveling from countries in the region.
2. Patients who are a member of a cluster of patients with severe acute respiratory 
illness (eg, fever and pneumonia requiring hospitalization) of unknown etiology 
in which MERS-CoV is being evaluated, in consultation with state and local 
health departments.
3. Patients with fever and symptoms of respiratory illness (eg, cough, shortness of 
breath) who have a history of being in a healthcare facility (as a patient, worker, 
or visitor) within 14 days before symptom onset in a country or territory in or 
near the Arabian Peninsula in which recent healthcare-associated cases of 
MERS-CoV have been identified.
Laboratory testing for suspected MERS-CoV cases in the United States can be performed 
using the CDC’s real-time reverse transcription polymerase chain reaction assay [19]. 
Testing of multiple specimens from different sites (ie, nasopharyngeal swab, oropharyngeal 
swab, sputum, serum, and stool/rectal swab) at different times after symptom onset is 
recommended to maximize the probability of MERS-CoV detection. Lower respiratory tract 
specimens (eg, sputum or bronchoalveolar lavage) and serum should be tested when possible 
because MERS-CoV infection has sometimes been detected in lower respiratory specimens 
or serum when upper respiratory specimens had tested negative, including in the 2 US cases 
[16, 17]. Most state health department laboratories in the United States are approved for 
MERS-CoV testing; clinicians should contact their state or local health department when 
evaluating a patient for MERS-CoV infection. If testing is not available through 
coordination with state and local health departments, samples can be sent to the CDC for 
testing [18]. Serologic testing, which is useful for making a retrospective diagnosis, is only 
available in the United States at the CDC.
Healthcare-associated infections have played a major role in the transmission of MERS-CoV 
[4, 9, 20–23]. Based on the experience with severe acute respiratory syndrome (SARS) 
coronavirus patients and early data from MERS-CoV, strict infection control practices 
prevent spread of infection [24]. Thus, the CDC recommends implementation of screening 
and triage procedures for early recognition of potentially infected patients and prompt 
institution of infection control measures, including standard, contact, and airborne 
precautions (airborne precautions include care in an airborne infection isolation room, eye 
protection with goggles or face shield, and respiratory protection at least as protective as a 
fit-tested N95 filtering facepiece respirator that has been National Institute for Occupational 
Safety and Health certified), to prevent secondary cases in healthcare workers or other 
patients [18]. Healthcare workers exposed to aerosol-generating procedures (eg, sputum 
induction, intubation, and airway suctioning) appear to be at particularly high risk [23]. A 
high degree of respiratory protection (ie, including airborne precautions) is currently 
recommended by the CDC because data on MERS-CoV transmission are limited; these 
guidelines are similar to what was recommended during the SARS response and will be 
updated as additional information becomes available.
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No specific vaccine or treatment is currently available for MERS-CoV. Many hospitalized 
patients become severely ill, with respiratory failure followed by multiorgan failure [8]. 
Clinical management focuses on supportive care [8, 16, 18]. In a small retrospective cohort 
study, 20 severely ill patients with MERS-CoV were treated with a combination of ribavirin 
and interferon alfa-2a, vs 24 patients in a comparison group. Improved survival in treated 
patients was noted at 14 days, but the results at 28 days were not statistically significant. A 
randomized controlled trial will be needed to determine if this treatment is of benefit [25].
No restrictions on travel to or from the Arabian Peninsula are recommended [26]. However, 
the CDC recommends that travelers protect themselves from MERS-CoV exposure by 
washing their hands frequently and avoiding close contact with ill persons. Given the 
emerging data on camels as a reservoir, the World Health Organization and the CDC 
recommend general hygiene measures (including regular handwashing before and after 
touching animals and avoiding contact with sick animals) for persons visiting farms, 
markets, or other places where animal contact is possible [26]. Consumption of raw or 
undercooked animal products, including camel milk, should also be avoided. Additional 
precautions that are recommended for persons at high risk for severe MERS (people with 
diabetes, kidney failure, chronic lung disease, or weakened immune systems) include 
avoiding contact with camels as well as consumption of raw camel milk and urine. In 
addition, people who are traveling to the region to provide healthcare services should review 
the CDC’s infection control guidelines for MERS [26]. Travelers from the region with onset 
of fever or respiratory symptoms during their trip or within 14 days of leaving the region 
should seek medical care. Before presenting for care, patients should inform the healthcare 
facility of their recent travel so appropriate isolation measures can be implemented.
To prevent further introduction of cases of MERS-CoV into the United States, the CDC has 
developed guidance for US travelers to countries in or near the Arabian Peninsula about 
MERS-CoV, including information aimed at those attending mass gatherings, such as the 
Hajj and Umrah [26], and public health messages about MERS have been posted at US 
airports. The CDC has also conducted MERS outreach with community-based organizations, 
travel agencies, institutes of higher learning, and businesses for travelers to the Arabian 
Peninsula. The CDC has also shared guidance to rapidly identify MERS-CoV cases among 
travelers to the United States with airlines, US Customs and Border Protection, and the US 
Transportation Security Administration.
The CDC is working with international partners to conduct studies aimed at better 
understanding MERS-CoV transmission and risk factors for illness in community and 
hospital settings. As new information becomes available, the CDC will update its 
recommendations [18]. MERS-CoV and Ebola virus disease remind us all of the 
interconnectedness of the United States to the rest of the world. With the increase in global 
travel, we must remain alert for emerging infectious diseases to protect US residents and the 
world from these public health threats.
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Figure 1. 
Number of confirmed cases of Middle East respiratory syndrome coronavirus infection 
(including those that were travel-associated) reported by the World Health Organization as 
of 25 February 2015, by month and year of illness onset—worldwide, 2012–2015 [2].
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